CINC424A2X01B Rollover Protocol

Key Inclusion criteria:

1. Patient is currently enrolled in a Novartis GDD or GMA-sponsored or Incyte-sponsoredclinical study, are receiving either ruxolitinib or combination of ruxolitinib andpanobinostat, and fulfilled all of the requirements of the parent protocol.

2. Patient is currently benefiting from the treatment with ruxolitinib monotherapy orcombination of ruxolitinib and panobinostat, as determined by the investigator

3. Patient has demonstrated compliance, as assessed by the investigator, with theparent study protocol requirements

4. Patient currently has no evidence of progressive disease, as determined by theinvestigator, following previous treatment with ruxolitinib or combination ofruxolitinib and panobinostat

Key Exclusion criteria:

1. Patient has been permanently discontinued from study treatment in the parent studydue to any reason.

2. Patient's indication is currently approved and reimbursed in the correspondingcountry for ruxolitinib monotherapy or combination of ruxolitinib and panobinostat.

3. Pregnant or nursing (lactating) women.

4. Female patients of childbearing potential (e.g. are menstruating) who do not agreeto abstinence or, if sexually active, do not agree to the use of highly effectivecontraception, throughout the study and for up to 30 days after stopping studytreatment.

Other protocol-defined Inclusion / Exclusion criteria may apply.